| Antimalarial pharmacology and therapeutics of atovaquone GL Nixon, DM Moss, AE Shone, DG Lalloo, N Fisher, PM O'Neill, SA Ward, ... Journal of Antimicrobial Chemotherapy 68 (5), 977-985, 2013 | 200 | 2013 |
| Antimalarial 4(1H)-pyridones bind to the Qi site of cytochrome bc1 MJ Capper, PM O’Neill, N Fisher, RW Strange, D Moss, SA Ward, ... Proceedings of the National Academy of Sciences 112 (3), 755-760, 2015 | 123 | 2015 |
| Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling DM Moss, M Siccardi British journal of pharmacology 171 (17), 3963-3979, 2014 | 109 | 2014 |
| The role of drug transporters in the kidney: lessons from tenofovir DM Moss, M Neary, A Owen Frontiers in pharmacology 5, 118145, 2014 | 92 | 2014 |
| Antitubercular pharmacodynamics of phenothiazines AJ Warman, TS Rito, NE Fisher, DM Moss, NG Berry, PM O'Neill, SA Ward, ... Journal of Antimicrobial Chemotherapy 68 (4), 869-880, 2013 | 74 | 2013 |
| Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir DM Moss, WS Kwan, NJ Liptrott, DL Smith, M Siccardi, SH Khoo, DJ Back, ... Antimicrobial agents and chemotherapy 55 (2), 879-887, 2011 | 71 | 2011 |
| Divalent Metals and pH Alter Raltegravir Disposition In Vitro DM Moss, M Siccardi, M Murphy, MM Piperakis, SH Khoo, DJ Back, ... Antimicrobial agents and chemotherapy 56 (6), 3020-3026, 2012 | 66 | 2012 |
| Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T> C polymorphism M Siccardi, A D'Avolio, S Nozza, M Simiele, L Baietto, FR Stefani, D Moss, ... Pharmacogenetics and genomics 20 (12), 759-765, 2010 | 58 | 2010 |
| Dietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancer E de Wolf, MI Abdullah, SM Jones, K Menezes, DM Moss, FP Drijfhout, ... Scientific reports 7 (1), 5410, 2017 | 56 | 2017 |
| Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies M Giardiello, NJ Liptrott, TO McDonald, D Moss, M Siccardi, P Martin, ... Nature communications 7 (1), 13184, 2016 | 55 | 2016 |
| Nanotechnologies in pancreatic cancer therapy A Manzur, A Oluwasanmi, D Moss, A Curtis, C Hoskins Pharmaceutics 9 (4), 39, 2017 | 52 | 2017 |
| Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis WD Hong, PD Gibbons, SC Leung, R Amewu, PA Stocks, A Stachulski, ... Journal of medicinal chemistry 60 (9), 3703-3726, 2017 | 48 | 2017 |
| The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery DM Moss, P Curley, H Kinvig, C Hoskins, A Owen Expert Review of Gastroenterology & Hepatology 12 (3), 223-236, 2018 | 43 | 2018 |
| Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation P Curley, RKR Rajoli, DM Moss, NJ Liptrott, S Letendre, A Owen, ... Antimicrobial agents and chemotherapy 61 (1), 10.1128/aac. 01841-16, 2017 | 40 | 2017 |
| Rilpivirine Inhibits Drug Transporters ABCB1, SLC22A1, and SLC22A2 In Vitro DM Moss, NJ Liptrott, P Curley, M Siccardi, DJ Back, A Owen Antimicrobial agents and chemotherapy 57 (11), 5612-5618, 2013 | 39 | 2013 |
| Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting M Siccardi, A D'Avolio, S Rodriguez-Novoa, L Cuenca, M Simiele, ... Therapeutic drug monitoring 34 (2), 232-235, 2012 | 39 | 2012 |
| Predicting intestinal absorption of raltegravir using a population-based ADME simulation DM Moss, M Siccardi, DJ Back, A Owen Journal of Antimicrobial Chemotherapy 68 (7), 1627-1634, 2013 | 36 | 2013 |
| The application of nanotechnology to drug delivery in medicine TO McDonald, M Siccardi, D Moss, N Liptrott, M Giardiello, S Rannard, ... Nanoengineering, 173-223, 2015 | 28 | 2015 |
| Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study RKR Rajoli, AT Podany, DM Moss, S Swindells, C Flexner, A Owen, ... The International Journal of Tuberculosis and Lung Disease 22 (8), 937-944, 2018 | 24 | 2018 |
| Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter DM Moss, NJ Liptrott, M Siccardi, A Owen Frontiers in pharmacology 6, 78, 2015 | 23 | 2015 |
